Unilife Corp

Unilife — Investor Presentation (April 2012)

21 slides from Unilife's investor presentation, Apr 18, 2012

  1. Slide 1: Australian Shareholder Briefing

    Exhibit 99.2 Australian Shareholder Briefing April 17, 2012 NASDAQ (UNIS) and ASX (UNS)

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our mana

  3. Slide 3: Everything in place, ready for execution

    Everything in place, ready for execution $40MM, 165,000sqf FDA-registered facility fully operational World-class management team with deep industry expertise Quality management system successfully audited on regular basis Diversified device portfolio driven by emerging customer needs Strong commerci

  4. Slide 4: Our Diversified Portfolio

    Our Diversified Portfolio Aligned to customer needs Differentiation Uniquely positioned to win April 17, 2012

  5. Slide 5: The Unifill syringe

    The Unifill syringe World’s First and Only Ready-to-fill Syringe with Integrated Safety

  6. Slide 6: Healthcare workers rate Unifill as Excellent

    Healthcare workers rate Unifill as Excellent How would you rate the feedback (audible click, tactile feel) received to confirm the activation of the needle retraction & the end of dose How would you rate the overall fit and finish, and quality of the syringe Mean Rating 1.2 1.1 Outcome Excellent Exc

  7. Slide 7: Self-Injecting Patients Rate Unifill as Excellent

    Self-Injecting Patients Rate Unifill as Excellent How would you rate the feedback (audible click, tactile feel) received to confirm the activation of the needle retraction & the end of dose How would you rate the overall fit and finish, and quality of the syringe Mean Rating 1.3 1.3 Outcome Excellen

  8. Slide 8: Human Factor Study Remarks

    Human Factor Study Remarks “All participants found the device and associated procedure to be easy to learn and easy to use, even the first attempt.” “The most appreciated feature of the syringe was the needle retraction mechanism, which was deemed safer and easier to utilize compared to other safety

  9. Slide 9: Needlestick Safety Advocacy Tour

    Needlestick Safety Advocacy Tour A grassroots campaign to engage healthcare personnel to raise awareness and minimize risk of needlestick injuries Building a database of 100,000 HCW and cause advocates 50 locations and 12 conferences across 36 cities over year

  10. Slide 10: The Pledge

    The Pledge I pledge to support Safe in Common in its campaign to promote and strengthen the Federal Needlestick Safety and Prevention Act, raise awareness of needlestick safety, and utilize safer engineering controls to better protect me and my fellow healthcare personnel from unnecessary needlestck

  11. Slide 11: A Unique Vehicle for Brand Differentiation

    A Unique Vehicle for Brand Differentiation April 17, 2012

  12. Slide 12: Unifill Select

    Unifill Select World’s First and Only Ready-to-fill Syringe with Integrated Safety and attachable needles

  13. Slide 13: EZMix

    EZMix The only dual or multi-chamber prefilled reconstitution syringe with integrated safety Considered a game-changer for drug reconstitution by numerous pharmaceutical companies

  14. Slide 14: Unifill, Unifill Select and EZMix

    Unifill, Unifill Select and EZMix Powerful Trio Covering Virtually Entire Prefilled Market April 17, 2012

  15. Slide 15: Unilife Rita Auto-Injector

    Unilife Rita Auto-Injector World’s First and Only Auto-Injector with a True End-of-Dose Indicator

  16. Slide 16: Comparison to Conventional Auto-Injector

    Comparison to Conventional Auto-Injector April 17, 2012

  17. Slide 17: Auto-Infusors

    Auto-Infusors Wearable single-use delivery system for doses 3mL or larger

  18. Slide 18: Novel Drug Delivery Devices

    Novel Drug Delivery Devices Many pipeline molecules targeting untreated conditions Target organs include brain, heart, eye, ear and nose siRNA*, gene therapy and cell based therapy Specialized (novel) devices can enable commercialization of these highly specialized drug molecules High value devices

  19. Slide 19: Building a Commercial Pipeline

    Building a Commercial Pipeline Multiple pharmaceutical customers Multiple therapeutic classes targeted Multiple devices now under negotiation Multiple types of agreement anticipated Multiple deals in the commercial pipeline April 17, 2012

  20. Slide 20: Key Upcoming Milestones

    Key Upcoming Milestones Continued Unifill supplies to current and new customers Unifill placement onto stability studies Potential for additional access or royalty fees Commercial supply agreements Potential ordering of additional higher volume assembly lines Agreements for additional products withi

  21. Slide 21: Questions and Answers

    Questions and Answers NASDAQ (UNIS) and ASX (UNS)

Unilife — Investor Presentation (April 2012) on 6ix